NDC product
Juxtapid
NDC 10122-402 · Chiesi USA, Inc.
Key facts
| Product NDC | 10122-402 |
|---|---|
| Proprietary name | Juxtapid |
| Nonproprietary name | lomitapide mesylate |
| Substances | LOMITAPIDE MESYLATE |
| Dosage form | CAPSULE |
| Route | ORAL |
| Labeler | Chiesi USA, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA203858 |
| Pharmacologic classes | Cytochrome P450 3A4 Inhibitors [MoA], Microsomal Triglyceride Transfer Protein Inhibitor [EPC], Microsomal Triglyceride Transfer Protein Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA] |
| Marketing start | Feb 25, 2026 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: